Drug Trial Radar · NCT07281716
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Dec 15, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- Dan FengAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Coherus Oncology, Inc.; Cantargia AB
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer. Phase 1b will assess dose-limiting toxicity (DLT), while Phase 2 will evaluate objective response rate (ORR), including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Exploratory analyses will investigate immunomodulatory effects through tumor and peripheral blood studies, and treatment will continue every 3 weeks for up to 1 year or until disease progression.
Conditions
- Metastatic Microsatellite Stable Colorectal Carcinoma
Interventions
NadunolimabDrug
5 mg/kg intravenously (IV) every 3 weeks (Q3W)
ToripalimabDrug
240 mg IV every 3 weeks (Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicities (DLTs)Time frame: The first cycle (day1 - day21) constitutes the DLT window.
- Objective Response Rate (ORR)Time frame: Treatment initiation through 12 months, or until documented disease progression or initiation of new anti-cancer therapy, whichever occurs first
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.